Auxly Cannabis Group wholly-owned subsidiaries, Dosecann and Kolab Project, have received amendments to their respective oil sales licences from Health Canada. These amendments authorize Dosecann and Kolab to sell cannabis extracts, edibles and topical products to the Canadian market.
The Cannabis Regulations require licenced processors to submit a notification to Health Canada of their intent to sell each novel cannabis product in Canada at least 60 calendar days before making such cannabis products available for sale. "Auxly, through its subsidiaries, has successfully submitted a total of 83 unique product SKUs to Health Canada for the new derivative product formats that the Company intends to offer for sale beginning in mid-December," the team with the company explains. "New products include vapes, chewables and chocolates, all of which have been formulated, developed and packaged to meet the regulatory requirements set out by Health Canada. These new product formats will be added to the Company’s current product portfolio already authorized for sale, such as oil-based products in, sprayable and capsule formats."
Hugo Alves, CEO of Auxly, commented: “We are delighted with the issuance of the licence amendments to Dosecann and Kolab and the successful submission of the required new product notifications for over 80 unique cannabis product SKUs under three of our cornerstone brands. These amendments and notifications are necessary regulatory milestones that must be achieved by any company wishing to sell derivative cannabis products when the 2.0 market begins later this year.”
For more information:
Auxly
[email protected]
auxly.com